Populations of infiltrated immune cells, such as CD163+ macrophages and CD8+ T cells, are associated with the prognosis in HCC, and immune cells in the tumor microenvironment can be a target for HCC therapy [46]. The gene discussed is CD8A; the disease is neoplasm.